Business ❯ Corporate Communications
Press Releases Webcasts Financial Reporting Public Relations Conference Calls Financial Disclosures Stakeholder Engagement Media Resources Earnings Announcements Public Disclosure Market Signals Shareholder Engagement Data Formats Financial News Meeting Notices Company Announcements Public Statements Regulatory Filings Market Analysis Analyst Call Disclosure Practices Take-Two Interactive Market Reactions
The company now targets an FDA filing in early 2026 following significant Week 16 mobility gains with no high‑grade toxicities reported.